S&P 5007,675.92▼0.4% Nasdaq26,749.30▼0.7% Dow51,245.74▼0.5% Russell 2K2,826.40▼0.4% 10-Yr5.12%+1bp VIX15.69+0.51 WTI$95.27▲3.4% Gold$4,292.50▼0.6% EUR/USD1.138▼0.6% BTC$84,310▼0.1% Nikkei65,514▲0.8%
At close · Thu, Sep 24, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Novo Nordisk shares fall after Phase 3 trial failure

Novo Nordisk shares fall after Phase 3 trial failure

Reported · Written up by our desk · Previews

Novo Nordisk’s stock fell on Friday after the company announced a Phase 3 trial failure, according to MarketWatch.

The news adds to investor concerns about the Danish healthcare company, after the trial outcome raised doubts about its broader pipeline.

← Newer storyAdam America and Stellar complete refi of 134-unit St. Cloud BTR proj…

More like this

EarningsCat owners boost spending even as dog demand cools
EarningsRestaurant stocks hover near 52-week lows amid weaker US traffic
EarningsMicron earnings next week put focus on customer deals and buybacks
EarningsMeta subscriptions and Muse lift shares, with Instagram IAP surge
EarningsNewAmsterdam Pharma wins European approval for cholesterol drugs

Sources

MarketWatchNovo Nordisk’s stock slumps after failed trial , adding to the company’s woes
MarketWatchNovo Nordisk’s stock slumps after failed trial , adding to the company’s woes

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.